



10th rEECur Newsletter

Issue 10

rEECur@trials.bham.ac.uk

11th April


TRIAL SUMMARY

Welcome to the 10th rEECur newsletter.


rEECur is a Multi-Arm, Multi-Stage (MAMS) phase II/phase III, International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. The trial has **recruited over 480 patients**. rEECur **recently opened in Austria**, making rEECur the largest randomised trial in this group of patients. Currently, rEECur is **open in a total of 185 sites across 17 countries**, with more sites planned still.

Three of the original four treatment arms have permanently closed on the basis that they had not shown sufficient evidence of activity based on response, progression-free survival and overall survival compared to Ifosfamide, (IFOS). We also introduced the Carboplatin and Etoposide arm to the study, as part of protocol v6.0, which is currently being directly compared to IFOS. The Data Monitoring Committee **congratulated all sites on data completeness** ahead of the recent interim analysis, with the highest data return level to date at >97%.

Recruitment by Country & Arm



rEECur Trial Schema



Easter Period Emergency Contact Details

The Cancer Research Clinical Trials Unit (CRCTU), Birmingham will be closed over the Easter period from **Friday 15th – Wednesday 20th April inclusive. Happy Easter!**



Dr Martin McCabe will provide emergency cover during this period. In the case of an emergency, please call the Christie Hospital switchboard on **+44161 446 3000** and ask to be put through to Dr Martin McCabe's mobile phone.

Please continue to report SAEs within 24 hours of becoming aware of the event to reg@trials.bham.ac.uk